Skip to main content

LAVALTRIE – June 19th, 2023 – Vetoquinol is proud to announce the launch of its newest antibiotic strength, Clavaseptin® 750 mg in Canada, today. This new strength will help owners to keep their furry companions healthy and happy.

Clavaseptin® 750 mg will offer the same effective treatment as the current available amoxiclav strengths, i.e. 50 mg, 62.5 mg, 250 mg and 500 mg. Veterinarians will have more options for large dogs and will be able to choose the strength that best fits their needs.

"We are thrilled to introduce our unique quadriscored amoxiclav in the Canadian market," said Isabelle Mongeau, Country Manager at Vetoquinol Canada. “This launch not only demonstrates our commitment to innovation and excellence in veterinary care, but also shows our willingness in answering needs of veterinarians, pet owners and their beloved pets."

It's important to note that Clavaseptin is intended for use in animals only and should not be used in humans. Additionally, it's crucial to follow the dosing and administration instructions provided by your veterinarian to ensure the best possible outcome for your pet.

For more information about our new Clavaseptin® 750 mg, please contact our Customer Experience Center at 1-800-565-0497.



 Vetoquinol is a leading international animal health company with operations in Europe, the Americas and Asia/Pacific. An independent " pure player," Vetoquinol innovates, develops and markets veterinary drugs and non-medicinal products for food-producing animals (bovines, swine) and companion animals (dogs, cats). Since its creation in 1933, Vetoquinol has been combining innovation and geographical diversification. The strengthening of the product portfolio and the acquisitions made in high-potential territories ensure hybrid growth for the Group. As of September 30, 2021, Vetoquinol employed 2,540 people. Vetoquinol has been listed on Euronext Paris since 2006 (stock code: VETO). Learn more about our journey and products by visiting